Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 45Carcinoma, Hepatocellular 13Osteosarcoma 8Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Sarcoma, Ewing 6Neuroendocrine Tumors 6Kidney Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Transitional Cell 4Carcinoma, Medullary 4Carcinoma 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Melanoma 3Endometrial Neoplasms 3Adrenocortical Carcinoma 3Wilms Tumor 2Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Refractory Prostate Cancer × cabozantinib × 1 year × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡